Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics.
Thomas FrisellEva BaecklundKarin BengtssonDaniela Di GiuseppeHelena Forsblad-d'EliaJohan Asklingnull nullPublished in: Annals of the rheumatic diseases (2017)
There was significant channelling of older and less healthy patients with RA to non-TNFi bDMARDs, in particular as first bDMARD. Whether this channelling represents a maximised benefit/risk ratio is unclear. Unless differences in age, medical history and disease activity are accounted for, they will substantially confound non-randomised comparative studies of available bDMARDs' safety and effectiveness.
Keyphrases
- disease activity
- rheumatoid arthritis
- systemic lupus erythematosus
- rheumatoid arthritis patients
- ankylosing spondylitis
- juvenile idiopathic arthritis
- clinical trial
- randomized controlled trial
- open label
- healthcare
- systematic review
- case report
- study protocol
- physical activity
- double blind
- interstitial lung disease
- case control
- systemic sclerosis
- breast cancer risk